CStone’s CS2009 trispecific antibody reinforces three clinical validations at ESMO
With data from over 300 patients across multiple tumor types and Phase 3 trials coming soon, the evidence supports CS2009’s mechanism, safety and antitumor efficacy Key Takeaways: CS2009 delivered strong…
Legend Biotech names new CEO
Cancer treatment maker Legend Biotech Corp. (LEGN.US) announced its appointment of a new CEO on Tuesday, a month and a half after the sudden departure of its longtime chief executive…
Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
Iza-bren was approved for recurrent or metastatic esophageal squamous cell carcinoma, after receiving earlier approval to treat nasopharyngeal carcinoma Key Takeaways: New approvals for Biokin’s Iza-bren highlight the rise of…
Chinese ‘Easter Eggs’ fall back to earth after wild year on Wall Street
Shares of Here Group, Zepp Health, Burning Rock Biotech and So-Young International all posted meteoric gains last year, but have given most of that back in 2026 Key Takeaways: A…
BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
Drug developer Legend Biotech Corp. (LEGN.US) on Tuesday reported its revenue rose 56% year-on-year to $305.1 million in the first quarter, as it reaped the benefit of strong sales for…
BRIEF: Legend Biotech posts strong fourth-quarter revenue gain
Legend Biotech Corp. (LEGN.US) on Tuesday reported strong double-digit revenue growth in last year’s fourth quarter on solid gains for its core Carvykti cancer treatment, lifting the company to a…
BRIEF: Hutchmed’s revenue drops 13% in 2025
Drug developer Hutchmed China Ltd. (HCM.US; 0013.HK) said on Thursday its revenue fell 13% in 2025 to $548.5 million from $630.2 million the previous year, as its profit rose sharply…
Recent Articles
RELATED ARTICLES
-
Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
688506.SHG
- AI in China’s medical aesthetics sector: From non-core services to clinical device integration
- Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
-
Akeso’s overseas drug promise fails to slow share decline
9926.HK
-
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
2617.HK
- Precision-drug maker Impact Therapeutics ignites IPO frenzy
-
Alphamab seals $2.2 billion licensing deal with AI biotech
9966.HK
